KP Sarcoma Syngeneic Model Overview
The KP sarcoma syngeneic model is a genetically defined murine soft tissue sarcoma derived from C57BL/6 mice engineered to harbor mutations in Kras and Trp53 genes. This model closely mirrors human undifferentiated pleomorphic sarcoma (UPS) and soft tissue sarcomas with complex karyotypes, providing a highly translational platform for studying oncogenic signaling, tumor–stroma interactions, and immune evasion.
When implanted subcutaneously or intramuscularly, KP sarcoma cells generate reproducible, moderately aggressive tumors characterized by spindle-cell morphology, dense stromal components, and immune suppression. The model’s defined genetic alterations and immunocompetent background make it particularly valuable for evaluating immunotherapies, targeted therapies, and radiation combinations in preclinical sarcoma research.
Request a Custom Quote for KP Sarcoma Syngeneic ModelBiological and Molecular Characteristics
The KP sarcoma cell line was derived from a genetically engineered mouse model in which conditional activation of oncogenic Kras and deletion of Trp53 led to spontaneous sarcoma formation. The resulting tumors exhibit robust activation of MAPK and PI3K-AKT signaling pathways, supporting rapid cell proliferation, angiogenesis, and fibroblast-like differentiation.
Molecular analysis of KP sarcoma tumors reveals high expression of vimentin, α-smooth muscle actin (α-SMA), and matrix metalloproteinases (MMPs), indicating strong mesenchymal features and matrix remodeling activity. The tumor microenvironment contains abundant macrophages, myeloid-derived suppressor cells, and fibroblasts, with limited infiltration by cytotoxic T lymphocytes. This composition recapitulates the immune-excluded phenotype common to high-grade human sarcomas and makes KP sarcoma an ideal model for testing immune-enhancing strategies.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Kras/Trp53-driven soft tissue sarcoma (mouse) |
| Histological type | Undifferentiated pleomorphic sarcoma |
| Inoculation route | Subcutaneous or intramuscular |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–6 days in vivo |
| Metastatic potential | Moderate; local invasion and rare lung metastasis |
| Immunophenotype | Immune-cold; macrophage- and fibroblast-dominant stroma |
| Common applications | Immunotherapy, radiation, targeted therapy, sarcoma biology studies |
In Vivo Model Development and Tumorigenicity
The KP sarcoma model is typically established by subcutaneous or intramuscular implantation of tumor cells derived from Kras/Trp53-mutant mice into immunocompetent C57BL/6 hosts. Subcutaneous tumors develop within 7–10 days and exhibit consistent growth kinetics suitable for efficacy testing and pharmacodynamic analysis. Intramuscular implantation provides a more physiologic environment for studying tumor–stroma interactions, vascular invasion, and radiation response.
KP sarcoma tumors grow moderately fast and maintain stable histology across serial passages. They show partial resistance to immune checkpoint inhibitors, reflecting an immune-cold phenotype similar to that of advanced human soft tissue sarcomas. This property makes the model particularly valuable for testing combination regimens that integrate immune activation, cytokine modulation, or targeted therapy to overcome resistance.
Request a Custom Quote for KP Sarcoma Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of KP sarcoma tumors reveals pleomorphic spindle cells arranged in fascicles within a fibrotic stroma. The tumors exhibit high nuclear atypia, frequent mitoses, and moderate vascularization. Areas of necrosis and stromal desmoplasia are common, accompanied by perivascular inflammatory infiltrates and macrophage accumulation.
Immunohistochemical staining demonstrates strong expression of vimentin and α-SMA, confirming mesenchymal differentiation, and high Ki-67 proliferation indices. CD31 staining highlights vascular structures, while F4/80 and CD11b identify abundant macrophage and myeloid cell infiltration. CD3 and CD8 staining reveal sparse T-cell presence, and PD-L1 expression is moderate but inducible under interferon exposure or immune modulation. These features collectively replicate the pathological hallmarks of undifferentiated pleomorphic sarcoma in humans.
Preclinical Applications and Drug Response
The KP sarcoma syngeneic model is widely used in translational oncology for investigating immune evasion, radiotherapy sensitization, and targeted pathway inhibition. It has been employed in studies evaluating PD-1 and CTLA-4 checkpoint blockade, often in combination with radiotherapy, macrophage-modulating agents, or TGF-beta inhibitors to enhance immune infiltration. The model has also been used to assess MEK and PI3K inhibitors targeting downstream effects of Kras activation.
Because KP sarcoma tumors exhibit resistance to monotherapy, they are ideal for testing rational combination strategies that integrate immune modulation with cytotoxic or targeted treatments. The model’s well-characterized genetic background, reproducible growth, and histopathological similarity to human soft tissue sarcomas make it a powerful platform for preclinical drug development and mechanistic studies of tumor–stroma interactions.
Request This Model
To request the KP sarcoma syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for KP Sarcoma Syngeneic Model